We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

MorphoSys Reports Filing for Phase 1b/2a Trial for its Lead Program MOR103 in Rheumatoid Arthritis

News   Jun 30, 2009

 
MorphoSys Reports Filing for Phase 1b/2a Trial for its Lead Program MOR103 in Rheumatoid Arthritis
 
 
Advertisement
 

RELATED ARTICLES

How Uromodulin Helps Against Urinary Tract Infections

News

The exact process by which uromodulin prevents inflammation had never been understood. Now an interdisciplinary team, drawn from three research groups at ETH Zurich together with researchers from the University of Zurich and the Children's Hospital Zurich, has filled this knowledge gap.

READ MORE

Hydroxychloroquine and Lopinavir/Ritonavir Treatment Arms for COVID-19 Discontinued

News

The World Health Organization (WHO) has accepted the recommendation from the Solidarity Trial’s International Steering Committee to discontinue hydroxychloroquine and lopinavir/ritonavir study arms.

READ MORE

Safer and More Efficient Method To Deliver Gene Therapy

News

Madison researchers have developed a safer and more efficient way to deliver a promising new method for treating cancer and liver disorders and for vaccination.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE